Interstitial Cystitis/Bladder Pain Syndrome¶

Chapter 54 | Part 2: Cardinal Manifestations and Presentation of Diseases

KEY CLINICAL POINTS¶

IC/BPS is a chronic condition characterized by bladder pain and urinary symptoms, with no definitive etiology. Definitions include bladder pain with LUTS >6 weeks, absence of infection, and no identifiable cause.
Etiology remains unclear but includes theories of urothelial dysfunction, autoimmune mechanisms, pelvic floor dysfunction, and central sensitization. No single cause explains the syndrome.
Management is multimodal, including conservative measures (dietary modifications, pelvic floor physiotherapy), medical therapies (PPS, DMSO, gabapentinoids), intravesical treatments, and surgical options for refractory cases.
Diagnosis relies on exclusion of other conditions, with key investigations including cystoscopy, hydrodistension, and symptom scores (ICSI, GUPI).
Prognosis is variable, with chronic pain and significant impact on quality of life. Complications include depression, suicidal ideation, and refractory symptoms requiring advanced interventions.

1. DEFINITION & OVERVIEW¶

Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a chronic condition characterized by bladder pain and urinary symptoms, with no definitive etiology. The NIDDK criteria define IC/BPS as an unpleasant sensation perceived to be related to the urinary bladder, associated with LUTS of >6 weeks’ duration, in the absence of infection or other identifiable causes. It encompasses two distinct disorders: IC/BPS (in men and women) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) in men. The condition is heterogeneous, with overlapping symptoms and potential central sensitization.

Table 54-1: Workup of Patients by a Primary Care Practitioner or General Internist¶

STEPS IN WORKUP	SPECIFICS
History/physical examination	Conduct a pelvic exam (recommended), including evaluation of the pelvic floor. Categorize symptoms as bladder/pelvis focused and/or extending beyond the pelvis.
Urine studies	Perform a microscopic urinalysis and urine culture with sensitivity testing.
Consideration of patient-centered treatment options	Begin with conservative measures. Introduce further symptom-specific treatments if satisfied with diagnosis.

STEPS IN WORKUP	SPECIFICS
Referral to an appropriate specialist	Referral should follow if: (cid:127) Diagnosis is unclear (cid:127) Microscopic or gross hematuria is present (cid:127) Condition is refractory to treatment (cid:127) Symptoms are severe (cid:127) Presentation is complex

1.1 Nomenclature and Definitions¶

IC/BPS is defined by the American Urological Association, Canadian Urological Association, and other groups as a chronic pelvic pain syndrome with bladder pain and LUTS. The term 'bladder pain syndrome' emphasizes the absence of a clear etiology. CP/CPPS refers to male-specific pain localized to the perineum and genitals. The MAPP Research Network identified distinct phenotypes, including 'bladder-only' and 'widespread pain' subtypes.

1.2 Clinical Phenotypes¶

Key phenotypes include: (1) Pelvic pain only (bladder-focused pain), (2) Widespread pain (pain beyond the pelvis), (3) Hunner lesions (distinct inflammatory ulcers), and (4) Psychosocial factors (depression, anxiety). The MAPP network identified these phenotypes through deep phenotyping studies, highlighting the need for individualized treatment.

2. EPIDEMIOLOGY¶

The prevalence of IC/BPS is difficult to determine due to evolving definitions and diagnostic criteria. It is estimated that 2.7–6.5% of North American women experience symptoms consistent with IC/BPS, but fewer than 10% have a confirmed diagnosis. The female-to-male ratio is 10:1, though underreporting in men is suspected. Risk factors include childhood UTIs, bowel dysfunction, sexual trauma, and comorbid conditions like IBS, fibromyalgia, and chronic fatigue syndrome. The condition is more common in women, with a higher prevalence in middle-aged and older populations.

2.1 Demographics¶

IC/BPS predominantly affects women, with a female-to-male ratio of 10:1. It is more common in middle-aged and older adults. Men may underreport symptoms due to societal stigma or lack of awareness. The condition is less prevalent in children and adolescents.

2.2 Comorbidities¶

Patients with IC/BPS frequently have comorbid conditions such as irritable bowel syndrome (40%), pelvic floor dysfunction (40–60%), vulvodynia (17%), fibromyalgia (36%), chronic fatigue syndrome (10%), and chronic back pain (47%). These conditions may share common pathophysiological mechanisms, such as central nervous system sensitization.

3. ETIOLOGY & PATHOPHYSIOLOGY¶

The etiology of IC/BPS remains unclear, with multiple theories proposed. Key mechanisms include urothelial dysfunction (glycosaminoglycan layer defects), autoimmune processes (B-cell clonotypes in Hunner lesions), pelvic floor dysfunction, and central sensitization. Infection and microbiome disturbances may contribute, though no definitive causative agent has been identified. The condition is considered a syndrome rather than a single disease, with overlapping pathophysiological pathways.

3.1 Urothelial Dysfunction¶

Defects in the glycosaminoglycan (GAG) layer of the urothelium may allow urine constituents to penetrate the bladder wall, triggering inflammation. Antiproliferative factor (APF) has been implicated in reduced urothelial cell proliferation, though its role remains controversial.

3.2 Autoimmune Mechanisms¶

Autoimmune processes, including B-cell clonotypes and anti-urothelial antibodies, are observed in some patients. Hunner lesions are associated with B-cell clonotypes, suggesting a role in disease pathogenesis. However, these findings are not universal and may represent a subset of patients.

3.3 Central Sensitization¶

Central sensitization and multisensory hypersensitivity are implicated in widespread pain phenotypes. Functional MRI and quantitative sensory testing (QST) studies show structural and functional brain differences in patients with UCPPS, supporting a central pain processing mechanism.

4. CLINICAL FEATURES¶

Patients present with varying degrees of bladder pain, urinary frequency, urgency, and pelvic discomfort. Symptoms may be associated with sexual dysfunction, depression, and anxiety. Flares are common, often exacerbated by diet, stress, or hormonal changes. The pain is often described as burning, pressure, or cramping, with radiation to the genitalia, abdomen, or perineum. Quality of life is significantly impacted, with many patients experiencing chronic pain and disability.

4.1 Symptomatology¶

Key symptoms include: - Bladder pain with filling or voiding - Urinary frequency and urgency - Pelvic or genital discomfort - Suprapubic tenderness - Sexual dysfunction - Flares associated with diet, stress, or menstrual cycles

4.2 Impact on Quality of Life¶

IC/BPS significantly affects daily functioning, social interactions, and mental health. Patients often report fatigue, depression, and suicidal ideation. The condition is associated with high disability and reduced quality of life, comparable to fibromyalgia and chronic back pain.

5. DIFFERENTIAL DIAGNOSIS¶

IC/BPS must be differentiated from other conditions causing pelvic pain and urinary symptoms, including interstitial cystitis (Hunner lesions), chronic prostatitis/CP/CPPS, bladder cancer, urinary tract infections (UTIs), and pelvic floor dysfunction. Other considerations include gynecological disorders, gastrointestinal issues, and psychosocial factors.

5.1 Confusable Conditions¶

Differential diagnoses include: - Bladder cancer - UTIs (especially in patients with hematuria) - Pelvic inflammatory disease - Endometriosis - Fibromyalgia - Chronic fatigue syndrome - Pelvic floor dysfunction - Psychological conditions (depression, anxiety)

5.2 Red Flags¶

Red flags for alternative diagnoses include: - Hematuria - Recurrent UTIs - Rapid progression of symptoms - Presence of systemic symptoms (e.g., fever, weight loss) - Abnormal imaging findings

6. INVESTIGATIONS & DIAGNOSIS¶

Diagnosis is based on exclusion of other conditions. Key investigations include cystoscopy, hydrodistension, urodynamic studies, and symptom scores (ICSI, GUPI). Urinalysis, urine culture, and pelvic floor examination are essential. The MAPP criteria emphasize symptom-based phenotyping and the role of central sensitization in diagnosis.

Table 54-2: Recommendations for Investigations in Patients with Suspected IC/BPS¶

MANDATORY	RECOMMENDED	OPTIONAL	NOT RECOMMENDED
History	Frequency/volume chart	Ultrasound/pelvic imaging	Potassium sensitivity test
Physical examination	Urinalysis	Postvoid residual	Urodynamics
Urine studies	Urine culture	Urine cytology	Bladder biopsy
Symptom scores	Intravesical anesthetic bladder challenge	Cystoscopy	Hydrodistension

6.1 Diagnostic Tests¶

Cystoscopy: Identifies Hunner lesions and excludes bladder cancer.
Hydrodistension: Assesses bladder capacity and pain response.
Urodynamic studies: Evaluates voiding dysfunction.
Urinalysis and culture: Rules out UTIs.
Symptom scores (ICSI, GUPI): Quantifies pain and urinary symptoms.

6.2 Diagnostic Criteria¶

The NIDDK criteria define IC/BPS as bladder pain with LUTS >6 weeks, absence of infection, and no identifiable cause. The MAPP criteria emphasize phenotyping (pelvic pain only vs. widespread pain) and central sensitization. A diagnosis of exclusion is required, with no single test confirming the condition.

7. MANAGEMENT & TREATMENT¶

Management is multimodal, combining conservative measures, medical therapies, and advanced interventions. Conservative approaches include dietary modifications, pelvic floor physiotherapy, and psychological support. Medical therapies include PPS, DMSO, gabapentinoids, and intravesical treatments. Surgical options are reserved for refractory cases.

7.1 Conservative Measures¶

Patient education and empowerment
Dietary modifications (avoid acidic/spicy foods, caffeine, alcohol)
Low-impact exercise
Pelvic floor physiotherapy
Sexual counseling
Stress management and mindfulness

7.2 Medical Therapies¶

PPS (oral): FDA-approved, though associated with vision-threatening maculopathy.
DMSO (intravesical): FDA-approved, though with halitosis side effects.
Gabapentinoids: Used for neuropathic pain.
Cyclosporine: For Hunner lesions.
Antimicrobials: For UTIs.
Antidepressants: For pain and comorbid depression.

7.3 Advanced Interventions¶

Intravesical therapies (lidocaine, heparin)
Sacral neuromodulation
Botulinum toxin A
Hydrodistension
Radical surgery (cystectomy, urinary diversion) for end-stage bladder

8. PROGNOSIS & COMPLICATIONS¶

IC/BPS is a chronic condition with variable prognosis. Most patients experience waxing and waning symptoms, though some progress to end-stage bladder. Complications include depression, suicidal ideation, and significant disability. The condition is associated with high healthcare costs and reduced quality of life, comparable to fibromyalgia and chronic back pain.

8.1 Long-Term Outcomes¶

Spontaneous improvement in 10–20% of patients.
50–70% experience persistent symptoms.
10–20% progress to end-stage bladder.
Chronic pain and disability are common, with significant impact on mental health.

8.2 Psychosocial Impact¶

High prevalence of depression (11–23% suicidal ideation).
Anxiety and stress exacerbate symptoms.
Social isolation and reduced quality of life.
Economic burden comparable to other chronic pain conditions.

9. SPECIAL CONSIDERATIONS¶

IC/BPS requires individualized management, with attention to psychosocial factors and comorbid conditions. Special considerations include: - Pregnancy: No specific risks, but symptoms may worsen. - Pediatrics: Rare, but possible in children with chronic pelvic pain. - Elderly: Higher risk of comorbidities and medication interactions. - Gender differences: Men may underreport symptoms, requiring targeted evaluation.

9.1 Psychosocial Factors¶

Depression and anxiety are common and worsen outcomes.
Cognitive behavioral therapy and mindfulness may improve symptoms.
Patient education and support are critical for long-term management.

9.2 Comorbid Conditions¶

IBS, fibromyalgia, and chronic fatigue syndrome are frequently comorbid.
Pelvic floor dysfunction and sexual dysfunction are common.
Psychosocial interventions are essential for managing comorbidities.

10. KEY POINTS & CLINICAL PEARLS¶

IC/BPS is a heterogeneous syndrome with no single etiology.
Diagnosis is based on exclusion of other conditions and symptom-based phenotyping.
Management is multimodal, combining conservative, medical, and advanced interventions.
Central sensitization and psychosocial factors play a significant role in pathophysiology.
Patient education, dietary modifications, and pelvic floor physiotherapy are foundational.
Surgical options are reserved for refractory cases.
Psychosocial support is critical for improving outcomes and quality of life.